Antiepileptic Drugs Market By Drug (First Generation, Second Generation, Third Generation) , By Route of Administration (Oral, Intravenous) By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores) : Global Opportunity Analysis and Industry Forecast, 2024-2033
The antiepileptic drugs market was valued at $16.8 billion in 2023, and is projected to reach $27.5 billion by 2033, growing at a CAGR of 5.1% from 2024 to 2033.
Antiepileptic drugs, also known as anticonvulsants, are medications formulated to prevent or reduce the frequency and severity of seizures in individuals with epilepsy. Epilepsy is a neurological disorder characterized by recurrent, unprovoked seizures resulting from abnormal electrical activity in the brain. Antiepileptic drugs work by stabilizing nerve cell membranes and modulating neurotransmitter activity to prevent this abnormal firing, helping to control seizure episodes.
The growth of the global antiepileptic drugs market is driven by alarming increase in prevalence of epilepsy and other neurological conditions. According to a study published by the World Health Organization in February 2024, approximately 50 million individuals suffer from epilepsy globally, thus making it the most common neurological disorders. In addition, improved diagnostic methods and growing awareness of epilepsy in healthcare systems contribute to earlier diagnoses and the expansion of the patient base for antiepileptic drugs. Moreover, surge in geriatric population notably contributes toward the growth of the global market. This is majorly attributed to the fact that aged individuals are more susceptible to falls, which can lead to head trauma. Traumatic brain injuries are a significant cause of seizures. As per the World Health Organization, the number of people aged 60 years and older was 1 billion in 2019. This number is estimated to increase to 1.4 billion by 2030 and 2.1 billion by 2050. Furthermore, significant government and healthcare support for epilepsy treatment acts as the key driving force of the global market. However, side effects associated with antiepileptic drugs such as drowsiness, dizziness, cognitive impairment, mood changes, and, in some cases, serious allergic reactions hamper the market growth. Moreover, availability of alternative non-pharmacological treatments, such as surgical interventions, ketogenic diets, and neuromodulation therapies restrains the market growth. On the contrary, ongoing R&D have led to the formulation of novel antiepileptic drugs with fewer side effects and improved efficacy and Innovations in drug delivery methods like extended release formulations are expected to offer lucrative opportunities for the expansion of the global market during the forecast period.
The global antiepileptic drugs industry is segmented into drug, route of administration, distribution channel, and region. By drug, the market is classified into first generation, second generation, third generation. On the basis of route of administration, it is divided into oral and intravenous. Depending on distribution channel, it is segregated into hospital pharmacies, retail pharmacies, online pharmacies, and drug stores. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
By drug, the second-generation segment held the highest market share in 2023.
On the basis of route of administration, the oral segment garnered the largest share in 2023.
Depending on distribution channel, the hospital segment was the major shareholder in 2023.
Region wise, North America held the highest market share in 2023, and is poised to maintain its leadership from 2024 to 2033.
Competition Analysis
Competitive analysis and profiles of the major players in the global antiepileptic drugs market include Johnson & Johnson, Merck KGaA, Eisai Co., Ltd., AstraZeneca, Novartis AG, Abbott Laboratories, Teva Pharmaceutical Industries Ltd., Pfizer Inc., GlaxoSmithKline Plc, and Sanofi. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and gain a strong foothold in the global market.
Key Market Segments
By Drug
First Generation
Second Generation
Third Generation
By Route Of Administration
Oral
Intravenous
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Drug Stores
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Johnson & Johnson
Merck KGaA
Eisai Co., Ltd.
AstraZeneca
Novartis AG
Abbott Laboratories
Teva Pharmaceutical Industries Ltd.
Pfizer Inc.
GlaxoSmithKline Plc
Sanofi
- CHAPTER 1: INTRODUCTION
- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits
- 1.4. Research Methodology
- 1.4.1. Primary Research
- 1.4.2. Secondary Research
- 1.4.3. Analyst Tools and Models
- CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
- CHAPTER 3: MARKET LANDSCAPE
- 3.1. Market Definition and Scope
- 3.2. Key Findings
- 3.2.1. Top Investment Pockets
- 3.2.2. Top Winning Strategies
- 3.3. Porter's Five Forces Analysis
- 3.3.1. Bargaining Power of Suppliers
- 3.3.2. Threat of New Entrants
- 3.3.3. Threat of Substitutes
- 3.3.4. Competitive Rivalry
- 3.3.5. Bargaining Power among Buyers
- 3.4. Market Dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities
- CHAPTER 4: ANTIEPILEPTIC DRUGS MARKET, BY DRUG
- 4.1. Market Overview
- 4.1.1 Market Size and Forecast, By Drug
- 4.2. First Generation
- 4.2.1. Key Market Trends, Growth Factors and Opportunities
- 4.2.2. Market Size and Forecast, By Region
- 4.2.3. Market Share Analysis, By Country
- 4.3. Second Generation
- 4.3.1. Key Market Trends, Growth Factors and Opportunities
- 4.3.2. Market Size and Forecast, By Region
- 4.3.3. Market Share Analysis, By Country
- 4.4. Third Generation
- 4.4.1. Key Market Trends, Growth Factors and Opportunities
- 4.4.2. Market Size and Forecast, By Region
- 4.4.3. Market Share Analysis, By Country
- CHAPTER 5: ANTIEPILEPTIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION
- 5.1. Market Overview
- 5.1.1 Market Size and Forecast, By Route Of Administration
- 5.2. Oral
- 5.2.1. Key Market Trends, Growth Factors and Opportunities
- 5.2.2. Market Size and Forecast, By Region
- 5.2.3. Market Share Analysis, By Country
- 5.3. Intravenous
- 5.3.1. Key Market Trends, Growth Factors and Opportunities
- 5.3.2. Market Size and Forecast, By Region
- 5.3.3. Market Share Analysis, By Country
- CHAPTER 6: ANTIEPILEPTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL
- 6.1. Market Overview
- 6.1.1 Market Size and Forecast, By Distribution Channel
- 6.2. Hospital Pharmacies
- 6.2.1. Key Market Trends, Growth Factors and Opportunities
- 6.2.2. Market Size and Forecast, By Region
- 6.2.3. Market Share Analysis, By Country
- 6.3. Retail Pharmacies
- 6.3.1. Key Market Trends, Growth Factors and Opportunities
- 6.3.2. Market Size and Forecast, By Region
- 6.3.3. Market Share Analysis, By Country
- 6.4. Online Pharmacies
- 6.4.1. Key Market Trends, Growth Factors and Opportunities
- 6.4.2. Market Size and Forecast, By Region
- 6.4.3. Market Share Analysis, By Country
- 6.5. Drug Stores
- 6.5.1. Key Market Trends, Growth Factors and Opportunities
- 6.5.2. Market Size and Forecast, By Region
- 6.5.3. Market Share Analysis, By Country
- CHAPTER 7: ANTIEPILEPTIC DRUGS MARKET, BY REGION
- 7.1. Market Overview
- 7.1.1 Market Size and Forecast, By Region
- 7.2. North America
- 7.2.1. Key Market Trends and Opportunities
- 7.2.2. Market Size and Forecast, By Drug
- 7.2.3. Market Size and Forecast, By Route Of Administration
- 7.2.4. Market Size and Forecast, By Distribution Channel
- 7.2.5. Market Size and Forecast, By Country
- 7.2.6. U.S. Antiepileptic Drugs Market
- 7.2.6.1. Market Size and Forecast, By Drug
- 7.2.6.2. Market Size and Forecast, By Route Of Administration
- 7.2.6.3. Market Size and Forecast, By Distribution Channel
- 7.2.7. Canada Antiepileptic Drugs Market
- 7.2.7.1. Market Size and Forecast, By Drug
- 7.2.7.2. Market Size and Forecast, By Route Of Administration
- 7.2.7.3. Market Size and Forecast, By Distribution Channel
- 7.2.8. Mexico Antiepileptic Drugs Market
- 7.2.8.1. Market Size and Forecast, By Drug
- 7.2.8.2. Market Size and Forecast, By Route Of Administration
- 7.2.8.3. Market Size and Forecast, By Distribution Channel
- 7.3. Europe
- 7.3.1. Key Market Trends and Opportunities
- 7.3.2. Market Size and Forecast, By Drug
- 7.3.3. Market Size and Forecast, By Route Of Administration
- 7.3.4. Market Size and Forecast, By Distribution Channel
- 7.3.5. Market Size and Forecast, By Country
- 7.3.6. Germany Antiepileptic Drugs Market
- 7.3.6.1. Market Size and Forecast, By Drug
- 7.3.6.2. Market Size and Forecast, By Route Of Administration
- 7.3.6.3. Market Size and Forecast, By Distribution Channel
- 7.3.7. France Antiepileptic Drugs Market
- 7.3.7.1. Market Size and Forecast, By Drug
- 7.3.7.2. Market Size and Forecast, By Route Of Administration
- 7.3.7.3. Market Size and Forecast, By Distribution Channel
- 7.3.8. UK Antiepileptic Drugs Market
- 7.3.8.1. Market Size and Forecast, By Drug
- 7.3.8.2. Market Size and Forecast, By Route Of Administration
- 7.3.8.3. Market Size and Forecast, By Distribution Channel
- 7.3.9. Italy Antiepileptic Drugs Market
- 7.3.9.1. Market Size and Forecast, By Drug
- 7.3.9.2. Market Size and Forecast, By Route Of Administration
- 7.3.9.3. Market Size and Forecast, By Distribution Channel
- 7.3.10. Spain Antiepileptic Drugs Market
- 7.3.10.1. Market Size and Forecast, By Drug
- 7.3.10.2. Market Size and Forecast, By Route Of Administration
- 7.3.10.3. Market Size and Forecast, By Distribution Channel
- 7.3.11. Rest Of Europe Antiepileptic Drugs Market
- 7.3.11.1. Market Size and Forecast, By Drug
- 7.3.11.2. Market Size and Forecast, By Route Of Administration
- 7.3.11.3. Market Size and Forecast, By Distribution Channel
- 7.4. Asia-Pacific
- 7.4.1. Key Market Trends and Opportunities
- 7.4.2. Market Size and Forecast, By Drug
- 7.4.3. Market Size and Forecast, By Route Of Administration
- 7.4.4. Market Size and Forecast, By Distribution Channel
- 7.4.5. Market Size and Forecast, By Country
- 7.4.6. Japan Antiepileptic Drugs Market
- 7.4.6.1. Market Size and Forecast, By Drug
- 7.4.6.2. Market Size and Forecast, By Route Of Administration
- 7.4.6.3. Market Size and Forecast, By Distribution Channel
- 7.4.7. China Antiepileptic Drugs Market
- 7.4.7.1. Market Size and Forecast, By Drug
- 7.4.7.2. Market Size and Forecast, By Route Of Administration
- 7.4.7.3. Market Size and Forecast, By Distribution Channel
- 7.4.8. Australia Antiepileptic Drugs Market
- 7.4.8.1. Market Size and Forecast, By Drug
- 7.4.8.2. Market Size and Forecast, By Route Of Administration
- 7.4.8.3. Market Size and Forecast, By Distribution Channel
- 7.4.9. India Antiepileptic Drugs Market
- 7.4.9.1. Market Size and Forecast, By Drug
- 7.4.9.2. Market Size and Forecast, By Route Of Administration
- 7.4.9.3. Market Size and Forecast, By Distribution Channel
- 7.4.10. South Korea Antiepileptic Drugs Market
- 7.4.10.1. Market Size and Forecast, By Drug
- 7.4.10.2. Market Size and Forecast, By Route Of Administration
- 7.4.10.3. Market Size and Forecast, By Distribution Channel
- 7.4.11. Rest of Asia-Pacific Antiepileptic Drugs Market
- 7.4.11.1. Market Size and Forecast, By Drug
- 7.4.11.2. Market Size and Forecast, By Route Of Administration
- 7.4.11.3. Market Size and Forecast, By Distribution Channel
- 7.5. LAMEA
- 7.5.1. Key Market Trends and Opportunities
- 7.5.2. Market Size and Forecast, By Drug
- 7.5.3. Market Size and Forecast, By Route Of Administration
- 7.5.4. Market Size and Forecast, By Distribution Channel
- 7.5.5. Market Size and Forecast, By Country
- 7.5.6. Brazil Antiepileptic Drugs Market
- 7.5.6.1. Market Size and Forecast, By Drug
- 7.5.6.2. Market Size and Forecast, By Route Of Administration
- 7.5.6.3. Market Size and Forecast, By Distribution Channel
- 7.5.7. Saudi Arabia Antiepileptic Drugs Market
- 7.5.7.1. Market Size and Forecast, By Drug
- 7.5.7.2. Market Size and Forecast, By Route Of Administration
- 7.5.7.3. Market Size and Forecast, By Distribution Channel
- 7.5.8. South Africa Antiepileptic Drugs Market
- 7.5.8.1. Market Size and Forecast, By Drug
- 7.5.8.2. Market Size and Forecast, By Route Of Administration
- 7.5.8.3. Market Size and Forecast, By Distribution Channel
- 7.5.9. Rest of LAMEA Antiepileptic Drugs Market
- 7.5.9.1. Market Size and Forecast, By Drug
- 7.5.9.2. Market Size and Forecast, By Route Of Administration
- 7.5.9.3. Market Size and Forecast, By Distribution Channel
- CHAPTER 8: COMPETITIVE LANDSCAPE
- 8.1. Introduction
- 8.2. Top Winning Strategies
- 8.3. Product Mapping Of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Top Player Positioning, 2023
- CHAPTER 9: COMPANY PROFILES
- 9.1. Johnson And Johnson
- 9.1.1. Company Overview
- 9.1.2. Key Executives
- 9.1.3. Company Snapshot
- 9.1.4. Operating Business Segments
- 9.1.5. Product Portfolio
- 9.1.6. Business Performance
- 9.1.7. Key Strategic Moves and Developments
- 9.2. Merck KGaA
- 9.2.1. Company Overview
- 9.2.2. Key Executives
- 9.2.3. Company Snapshot
- 9.2.4. Operating Business Segments
- 9.2.5. Product Portfolio
- 9.2.6. Business Performance
- 9.2.7. Key Strategic Moves and Developments
- 9.3. Eisai Co., Ltd.
- 9.3.1. Company Overview
- 9.3.2. Key Executives
- 9.3.3. Company Snapshot
- 9.3.4. Operating Business Segments
- 9.3.5. Product Portfolio
- 9.3.6. Business Performance
- 9.3.7. Key Strategic Moves and Developments
- 9.4. AstraZeneca
- 9.4.1. Company Overview
- 9.4.2. Key Executives
- 9.4.3. Company Snapshot
- 9.4.4. Operating Business Segments
- 9.4.5. Product Portfolio
- 9.4.6. Business Performance
- 9.4.7. Key Strategic Moves and Developments
- 9.5. Novartis AG
- 9.5.1. Company Overview
- 9.5.2. Key Executives
- 9.5.3. Company Snapshot
- 9.5.4. Operating Business Segments
- 9.5.5. Product Portfolio
- 9.5.6. Business Performance
- 9.5.7. Key Strategic Moves and Developments
- 9.6. Abbott Laboratories
- 9.6.1. Company Overview
- 9.6.2. Key Executives
- 9.6.3. Company Snapshot
- 9.6.4. Operating Business Segments
- 9.6.5. Product Portfolio
- 9.6.6. Business Performance
- 9.6.7. Key Strategic Moves and Developments
- 9.7. Teva Pharmaceutical Industries Ltd.
- 9.7.1. Company Overview
- 9.7.2. Key Executives
- 9.7.3. Company Snapshot
- 9.7.4. Operating Business Segments
- 9.7.5. Product Portfolio
- 9.7.6. Business Performance
- 9.7.7. Key Strategic Moves and Developments
- 9.8. Pfizer Inc.
- 9.8.1. Company Overview
- 9.8.2. Key Executives
- 9.8.3. Company Snapshot
- 9.8.4. Operating Business Segments
- 9.8.5. Product Portfolio
- 9.8.6. Business Performance
- 9.8.7. Key Strategic Moves and Developments
- 9.9. GlaxoSmithKline Plc
- 9.9.1. Company Overview
- 9.9.2. Key Executives
- 9.9.3. Company Snapshot
- 9.9.4. Operating Business Segments
- 9.9.5. Product Portfolio
- 9.9.6. Business Performance
- 9.9.7. Key Strategic Moves and Developments
- 9.10. Sanofi
- 9.10.1. Company Overview
- 9.10.2. Key Executives
- 9.10.3. Company Snapshot
- 9.10.4. Operating Business Segments
- 9.10.5. Product Portfolio
- 9.10.6. Business Performance
- 9.10.7. Key Strategic Moves and Developments
- LIST OF TABLES
- TABLE 1. GLOBAL ANTIEPILEPTIC DRUGS MARKET, BY DRUG, 2024 - 2033 ($BILLION)
- TABLE 2. ANTIEPILEPTIC DRUGS MARKET FOR FIRST GENERATION, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 3. ANTIEPILEPTIC DRUGS MARKET FOR SECOND GENERATION, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 4. ANTIEPILEPTIC DRUGS MARKET FOR THIRD GENERATION, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 5. GLOBAL ANTIEPILEPTIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
- TABLE 6. ANTIEPILEPTIC DRUGS MARKET FOR ORAL, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 7. ANTIEPILEPTIC DRUGS MARKET FOR INTRAVENOUS, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 8. GLOBAL ANTIEPILEPTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 9. ANTIEPILEPTIC DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 10. ANTIEPILEPTIC DRUGS MARKET FOR RETAIL PHARMACIES, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 11. ANTIEPILEPTIC DRUGS MARKET FOR ONLINE PHARMACIES, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 12. ANTIEPILEPTIC DRUGS MARKET FOR DRUG STORES, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 13. ANTIEPILEPTIC DRUGS MARKET, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 14. NORTH AMERICA ANTIEPILEPTIC DRUGS MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 15. NORTH AMERICA ANTIEPILEPTIC DRUGS MARKET, BY DRUG, 2024 - 2033 ($BILLION)
- TABLE 16. NORTH AMERICA ANTIEPILEPTIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
- TABLE 17. NORTH AMERICA ANTIEPILEPTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 18. U.S. ANTIEPILEPTIC DRUGS MARKET, BY DRUG, 2024 - 2033 ($BILLION)
- TABLE 19. U.S. ANTIEPILEPTIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
- TABLE 20. U.S. ANTIEPILEPTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 21. CANADA ANTIEPILEPTIC DRUGS MARKET, BY DRUG, 2024 - 2033 ($BILLION)
- TABLE 22. CANADA ANTIEPILEPTIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
- TABLE 23. CANADA ANTIEPILEPTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 24. MEXICO ANTIEPILEPTIC DRUGS MARKET, BY DRUG, 2024 - 2033 ($BILLION)
- TABLE 25. MEXICO ANTIEPILEPTIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
- TABLE 26. MEXICO ANTIEPILEPTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 27. EUROPE ANTIEPILEPTIC DRUGS MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 28. EUROPE ANTIEPILEPTIC DRUGS MARKET, BY DRUG, 2024 - 2033 ($BILLION)
- TABLE 29. EUROPE ANTIEPILEPTIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
- TABLE 30. EUROPE ANTIEPILEPTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 31. GERMANY ANTIEPILEPTIC DRUGS MARKET, BY DRUG, 2024 - 2033 ($BILLION)
- TABLE 32. GERMANY ANTIEPILEPTIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
- TABLE 33. GERMANY ANTIEPILEPTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 34. FRANCE ANTIEPILEPTIC DRUGS MARKET, BY DRUG, 2024 - 2033 ($BILLION)
- TABLE 35. FRANCE ANTIEPILEPTIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
- TABLE 36. FRANCE ANTIEPILEPTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 37. UK ANTIEPILEPTIC DRUGS MARKET, BY DRUG, 2024 - 2033 ($BILLION)
- TABLE 38. UK ANTIEPILEPTIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
- TABLE 39. UK ANTIEPILEPTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 40. ITALY ANTIEPILEPTIC DRUGS MARKET, BY DRUG, 2024 - 2033 ($BILLION)
- TABLE 41. ITALY ANTIEPILEPTIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
- TABLE 42. ITALY ANTIEPILEPTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 43. SPAIN ANTIEPILEPTIC DRUGS MARKET, BY DRUG, 2024 - 2033 ($BILLION)
- TABLE 44. SPAIN ANTIEPILEPTIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
- TABLE 45. SPAIN ANTIEPILEPTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 46. REST OF EUROPE ANTIEPILEPTIC DRUGS MARKET, BY DRUG, 2024 - 2033 ($BILLION)
- TABLE 47. REST OF EUROPE ANTIEPILEPTIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
- TABLE 48. REST OF EUROPE ANTIEPILEPTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 49. ASIA-PACIFIC ANTIEPILEPTIC DRUGS MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 50. ASIA-PACIFIC ANTIEPILEPTIC DRUGS MARKET, BY DRUG, 2024 - 2033 ($BILLION)
- TABLE 51. ASIA-PACIFIC ANTIEPILEPTIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
- TABLE 52. ASIA-PACIFIC ANTIEPILEPTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 53. JAPAN ANTIEPILEPTIC DRUGS MARKET, BY DRUG, 2024 - 2033 ($BILLION)
- TABLE 54. JAPAN ANTIEPILEPTIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
- TABLE 55. JAPAN ANTIEPILEPTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 56. CHINA ANTIEPILEPTIC DRUGS MARKET, BY DRUG, 2024 - 2033 ($BILLION)
- TABLE 57. CHINA ANTIEPILEPTIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
- TABLE 58. CHINA ANTIEPILEPTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 59. AUSTRALIA ANTIEPILEPTIC DRUGS MARKET, BY DRUG, 2024 - 2033 ($BILLION)
- TABLE 60. AUSTRALIA ANTIEPILEPTIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
- TABLE 61. AUSTRALIA ANTIEPILEPTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 62. INDIA ANTIEPILEPTIC DRUGS MARKET, BY DRUG, 2024 - 2033 ($BILLION)
- TABLE 63. INDIA ANTIEPILEPTIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
- TABLE 64. INDIA ANTIEPILEPTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 65. SOUTH KOREA ANTIEPILEPTIC DRUGS MARKET, BY DRUG, 2024 - 2033 ($BILLION)
- TABLE 66. SOUTH KOREA ANTIEPILEPTIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
- TABLE 67. SOUTH KOREA ANTIEPILEPTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 68. REST OF ASIA-PACIFIC ANTIEPILEPTIC DRUGS MARKET, BY DRUG, 2024 - 2033 ($BILLION)
- TABLE 69. REST OF ASIA-PACIFIC ANTIEPILEPTIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
- TABLE 70. REST OF ASIA-PACIFIC ANTIEPILEPTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 71. LAMEA ANTIEPILEPTIC DRUGS MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 72. LAMEA ANTIEPILEPTIC DRUGS MARKET, BY DRUG, 2024 - 2033 ($BILLION)
- TABLE 73. LAMEA ANTIEPILEPTIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
- TABLE 74. LAMEA ANTIEPILEPTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 75. BRAZIL ANTIEPILEPTIC DRUGS MARKET, BY DRUG, 2024 - 2033 ($BILLION)
- TABLE 76. BRAZIL ANTIEPILEPTIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
- TABLE 77. BRAZIL ANTIEPILEPTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 78. SAUDI ARABIA ANTIEPILEPTIC DRUGS MARKET, BY DRUG, 2024 - 2033 ($BILLION)
- TABLE 79. SAUDI ARABIA ANTIEPILEPTIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
- TABLE 80. SAUDI ARABIA ANTIEPILEPTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 81. SOUTH AFRICA ANTIEPILEPTIC DRUGS MARKET, BY DRUG, 2024 - 2033 ($BILLION)
- TABLE 82. SOUTH AFRICA ANTIEPILEPTIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
- TABLE 83. SOUTH AFRICA ANTIEPILEPTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 84. REST OF LAMEA ANTIEPILEPTIC DRUGS MARKET, BY DRUG, 2024 - 2033 ($BILLION)
- TABLE 85. REST OF LAMEA ANTIEPILEPTIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
- TABLE 86. REST OF LAMEA ANTIEPILEPTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 87. JOHNSON AND JOHNSON: KEY EXECUTIVES
- TABLE 88. JOHNSON AND JOHNSON: COMPANY SNAPSHOT
- TABLE 89. JOHNSON AND JOHNSON: OPERATING SEGMENTS
- TABLE 90. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
- TABLE 91. JOHNSON AND JOHNSON: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 92. MERCK KGAA: KEY EXECUTIVES
- TABLE 93. MERCK KGAA: COMPANY SNAPSHOT
- TABLE 94. MERCK KGAA: OPERATING SEGMENTS
- TABLE 95. MERCK KGAA: PRODUCT PORTFOLIO
- TABLE 96. MERCK KGAA: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 97. EISAI CO., LTD.: KEY EXECUTIVES
- TABLE 98. EISAI CO., LTD.: COMPANY SNAPSHOT
- TABLE 99. EISAI CO., LTD.: OPERATING SEGMENTS
- TABLE 100. EISAI CO., LTD.: PRODUCT PORTFOLIO
- TABLE 101. EISAI CO., LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 102. ASTRAZENECA: KEY EXECUTIVES
- TABLE 103. ASTRAZENECA: COMPANY SNAPSHOT
- TABLE 104. ASTRAZENECA: OPERATING SEGMENTS
- TABLE 105. ASTRAZENECA: PRODUCT PORTFOLIO
- TABLE 106. ASTRAZENECA: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 107. NOVARTIS AG: KEY EXECUTIVES
- TABLE 108. NOVARTIS AG: COMPANY SNAPSHOT
- TABLE 109. NOVARTIS AG: OPERATING SEGMENTS
- TABLE 110. NOVARTIS AG: PRODUCT PORTFOLIO
- TABLE 111. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 112. ABBOTT LABORATORIES: KEY EXECUTIVES
- TABLE 113. ABBOTT LABORATORIES: COMPANY SNAPSHOT
- TABLE 114. ABBOTT LABORATORIES: OPERATING SEGMENTS
- TABLE 115. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
- TABLE 116. ABBOTT LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 117. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
- TABLE 118. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
- TABLE 119. TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
- TABLE 120. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
- TABLE 121. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 122. PFIZER INC.: KEY EXECUTIVES
- TABLE 123. PFIZER INC.: COMPANY SNAPSHOT
- TABLE 124. PFIZER INC.: OPERATING SEGMENTS
- TABLE 125. PFIZER INC.: PRODUCT PORTFOLIO
- TABLE 126. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 127. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
- TABLE 128. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
- TABLE 129. GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
- TABLE 130. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
- TABLE 131. GLAXOSMITHKLINE PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 132. SANOFI: KEY EXECUTIVES
- TABLE 133. SANOFI: COMPANY SNAPSHOT
- TABLE 134. SANOFI: OPERATING SEGMENTS
- TABLE 135. SANOFI: PRODUCT PORTFOLIO
- TABLE 136. SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS
- LIST OF FIGURES
- FIGURE 1. GLOBAL ANTIEPILEPTIC DRUGS MARKET, 2024 - 2033
- FIGURE 2. SEGMENTATION OF ANTIEPILEPTIC DRUGS MARKET, 2024 - 2033
- FIGURE 3. TOP INVESTMENT POCKET IN ANTIEPILEPTIC DRUGS MARKET
- FIGURE 4. MODERATE BARGAINING POWER OF BUYERS
- FIGURE 5. MODERATE BARGAINING POWER OF SUPPLIERS
- FIGURE 6. MODERATE THREAT OF NEW ENTRANTS
- FIGURE 7. LOW THREAT OF SUBSTITUTION
- FIGURE 8. HIGH COMPETITIVE RIVALRY
- FIGURE 9. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALANTIEPILEPTIC DRUGS MARKET
- FIGURE 10. GLOBAL ANTIEPILEPTIC DRUGS MARKET SEGMENTATION, BY DRUG
- FIGURE 11. ANTIEPILEPTIC DRUGS MARKET FOR FIRST GENERATION, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 12. ANTIEPILEPTIC DRUGS MARKET FOR SECOND GENERATION, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 13. ANTIEPILEPTIC DRUGS MARKET FOR THIRD GENERATION, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 14. GLOBAL ANTIEPILEPTIC DRUGS MARKET SEGMENTATION, BY ROUTE OF ADMINISTRATION
- FIGURE 15. ANTIEPILEPTIC DRUGS MARKET FOR ORAL, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 16. ANTIEPILEPTIC DRUGS MARKET FOR INTRAVENOUS, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 17. GLOBAL ANTIEPILEPTIC DRUGS MARKET SEGMENTATION, BY DISTRIBUTION CHANNEL
- FIGURE 18. ANTIEPILEPTIC DRUGS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 19. ANTIEPILEPTIC DRUGS MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 20. ANTIEPILEPTIC DRUGS MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 21. ANTIEPILEPTIC DRUGS MARKET FOR DRUG STORES, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 22. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*
- FIGURE 23. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*
- FIGURE 24. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*
- FIGURE 25. PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 26. COMPETITIVE DASHBOARD
- FIGURE 27. COMPETITIVE HEATMAP: ANTIEPILEPTIC DRUGS MARKET
- FIGURE 28. TOP PLAYER POSITIONING, 2023
- FIGURE 29. JOHNSON AND JOHNSON: NET SALES, 2021-2023 ($BILLION)
- FIGURE 30. JOHNSON AND JOHNSON: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 31. JOHNSON AND JOHNSON: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 32. MERCK KGAA: NET SALES, 2021-2023 ($BILLION)
- FIGURE 33. MERCK KGAA: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 34. MERCK KGAA: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 35. EISAI CO., LTD.: NET SALES, 2021-2023 ($BILLION)
- FIGURE 36. EISAI CO., LTD.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 37. EISAI CO., LTD.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 38. ASTRAZENECA: NET SALES, 2021-2023 ($BILLION)
- FIGURE 39. ASTRAZENECA: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 40. ASTRAZENECA: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 41. NOVARTIS AG: NET SALES, 2021-2023 ($BILLION)
- FIGURE 42. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 43. NOVARTIS AG: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 44. ABBOTT LABORATORIES: NET SALES, 2021-2023 ($BILLION)
- FIGURE 45. ABBOTT LABORATORIES: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 46. ABBOTT LABORATORIES: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 47. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES, 2021-2023 ($BILLION)
- FIGURE 48. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 49. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 50. PFIZER INC.: NET SALES, 2021-2023 ($BILLION)
- FIGURE 51. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 52. PFIZER INC.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 53. GLAXOSMITHKLINE PLC: NET SALES, 2021-2023 ($BILLION)
- FIGURE 54. GLAXOSMITHKLINE PLC: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 55. GLAXOSMITHKLINE PLC: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 56. SANOFI: NET SALES, 2021-2023 ($BILLION)
- FIGURE 57. SANOFI: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 58. SANOFI: REVENUE SHARE, BY REGION, 2023 (%)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook